Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of DCC-3014 in Japanese adults with tenosynovial giant cell tumor
jRCT2031260479Phase 2Not yet recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Oct 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vimseltinib in tenosynovial giant cell tumor (TGCT), sponsored by Ono Pharmaceutical. Primary endpoint: Objective response rate at Week 24 per independent radiological review. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
vimseltinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on jRCT2031260479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260479.